Search in the Abstract Database

Search Abstracts 2016

* = Presenting author

P559 Awareness of human papilloma virus infection amongst women with inflammatory bowel diseases: results from patients’ survey

V. Suchá*1, B. Kadleckova2, B. Repakova2, K. Otottova2, L. Jurgos3, S. Kinova4, Z. Zelinkova2

1Outpatient Department of Gastroenterology, Jurgos s.r.o., Bratislava, Slovakia, 2IBD Centre, Assiduo, Bratislava, Slovakia, 3Outpatient Department of Gastroenterology, Jurgos s.r.o,, Bratislava, Slovakia, 4Faculty of Medicine, Comenius University, First Department of Internal Medicine, Bratislava, Slovakia


It has been suggested that women with inflammatory bowel disease (IBD) using immune suppressive (IS) therapy may be at increased risk of human papilloma virus (HPV) infection. However, no conclusive data are currently available on the real effect of IS therapy on incidence and carcinogenic potential of HPV infection in this setting. With the lack of clear guidelines on gynaecological surveillance of IBD patients on IS treatment, patients’ awareness represents an important tool for preventing HPV progression. Therefore, the aim of our study was, first, to evaluate the compliance of IBD female patients with the general cervical cancer screening procedure and, second, to assess their awareness of HPV infection.


We administrated a questionnaire to a random selection of women with IBD in one referral centre. The survey included questions on demographics, medical history, frequency of gynaecological visits, and their HPV status.


In total, 124 IBD patients completed the survey (mean age 41 years, range 21–80 years). The treatment used at the moment of the survey comprised 5-aminosalycilates (72 pts, 58.0%), systemic corticosteroids (10 pts, 8.1%), azathioprine (55 pts, 44.3%), anti-TNF biologics (37 pts, 29.8%), and one-third of patients (25.0%) were on combined immunosuppression.

Overall, 100 pts (81%) followed regular screenings procedures at the gynaecologist. Further, 76 pts (61%) reported visiting their gynaecologist once a year; 16 pts (13%) more than once a year; 9 pts (7%) every 2 years; and 20 pts (16%) visited their gynaecologist irregularly. Only 79% of the patients undergoing regular gynaecological examinations had Pap smear during these exams. In addition, only 65% of these patients reported to know the result of their last Pap smear. Regarding HPV status, only the minority (40%) of women knew whether they were HPV positive or not. There were no differences in the awareness of HPV status, neither in the attendance of regular gynaecological visits between patients with and without immune suppressive therapy. Nearly one-third of women had never heard of HPV.


The awareness of HPV infection amongst IBD female population is poor. In general, the compliance with the general gynaecological screening procedure is unsatisfactory, and a substantial proportion of patients lack the knowledge of their own HPV status.